Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1007

1.

Patient-derived renal cell carcinoma cells fused with allogeneic dendritic cells elicit anti-tumor activity: in vitro results and clinical responses.

Zhou J, Weng D, Zhou F, Pan K, Song H, Wang Q, Wang H, Wang H, Li Y, Huang L, Zhang H, Huang W, Xia J.

Cancer Immunol Immunother. 2009 Oct;58(10):1587-97. doi: 10.1007/s00262-009-0668-9. Epub 2009 Feb 17.

PMID:
19221746
2.

Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma.

Avigan DE, Vasir B, George DJ, Oh WK, Atkins MB, McDermott DF, Kantoff PW, Figlin RA, Vasconcelles MJ, Xu Y, Kufe D, Bukowski RM.

J Immunother. 2007 Oct;30(7):749-61.

PMID:
17893567
3.

[Efficacy of autologous renal tumor cell lysate-loaded dendritic cell vaccine in combination with cytokine-induced killer cells on advanced renal cell carcinoma--a report of ten cases].

Wang H, Zhou FJ, Wang QJ, Qin ZK, Huang LX, Liu ZW, Han H, Li YQ, Chen SP, Xia JC.

Ai Zheng. 2006 May;25(5):625-30. Chinese.

PMID:
16687087
4.

Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients.

Wierecky J, Müller MR, Wirths S, Halder-Oehler E, Dörfel D, Schmidt SM, Häntschel M, Brugger W, Schröder S, Horger MS, Kanz L, Brossart P.

Cancer Res. 2006 Jun 1;66(11):5910-8.

5.

Cytotoxic effector cells with antitumor activity can be amplified ex vivo from biopsies or blood of patients with renal cell carcinoma for cell therapy use.

Bouet-Toussaint F, Patard JJ, Gervais A, Genetet N, de la Pintière CT, Rioux-Leclercq N, Toutirais O, Thirouard AS, Ramée MP, Catros-Quemener V.

Cancer Immunol Immunother. 2003 Nov;52(11):699-707. Epub 2003 Jul 15.

PMID:
12879292
6.

Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a phase 1 study.

Oosterwijk-Wakka JC, Tiemessen DM, Bleumer I, de Vries IJ, Jongmans W, Adema GJ, Debruyne FM, de Mulder PH, Oosterwijk E, Mulders PF.

J Immunother. 2002 Nov-Dec;25(6):500-8.

PMID:
12439347
7.

Superior anti-tumor protection and therapeutic efficacy of vaccination with allogeneic and semiallogeneic dendritic cell/tumor cell fusion hybrids for murine colon adenocarcinoma.

Yasuda T, Kamigaki T, Kawasaki K, Nakamura T, Yamamoto M, Kanemitsu K, Takase S, Kuroda D, Kim Y, Ajiki T, Kuroda Y.

Cancer Immunol Immunother. 2007 Jul;56(7):1025-36. Epub 2006 Nov 28.

PMID:
17131118
8.

Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.

Tso CL, Zisman A, Pantuck A, Calilliw R, Hernandez JM, Paik S, Nguyen D, Gitlitz B, Shintaku PI, de Kernion J, Figlin R, Belldegrun A.

Cancer Res. 2001 Nov 1;61(21):7925-33.

9.
10.

Immune responses in patients with metastatic renal cell carcinoma treated with dendritic cells pulsed with tumor lysate.

Soleimani A, Berntsen A, Svane IM, Pedersen AE.

Scand J Immunol. 2009 Nov;70(5):481-9. doi: 10.1111/j.1365-3083.2009.02322.x.

11.

Superior antitumor in vitro responses of allogeneic matched sibling compared with autologous patient CD8+ T cells.

Kausche S, Wehler T, Schnürer E, Lennerz V, Brenner W, Melchior S, Gröne M, Nonn M, Strand S, Meyer R, Ranieri E, Huber C, Falk CS, Herr W.

Cancer Res. 2006 Dec 1;66(23):11447-54.

12.

In vitro activation of cancer patient-derived dendritic cells by tumor cells genetically modified to express CD154.

Loskog A, Tötterman TH, Böhle A, Brandau S.

Cancer Gene Ther. 2002 Oct;9(10):846-53.

13.

Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.

Palucka AK, Ueno H, Connolly J, Kerneis-Norvell F, Blanck JP, Johnston DA, Fay J, Banchereau J.

J Immunother. 2006 Sep-Oct;29(5):545-57.

PMID:
16971810
14.

Induction of autologous tumor-specific cytotoxic T-lymphocyte activity against a human renal carcinoma cell line by B7-1 (CD8O) costimulation.

Wang YC, Zhu L, McHugh R, Graham SD Jr, Hillyer CD, Dillehay D, Sell KW, Selvaraj P.

J Immunother Emphasis Tumor Immunol. 1996 Jan;19(1):1-8.

PMID:
9147700
15.

Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells.

Koido S, Hara E, Homma S, Torii A, Toyama Y, Kawahara H, Watanabe M, Yanaga K, Fujise K, Tajiri H, Gong J, Toda G.

Clin Cancer Res. 2005 Nov 1;11(21):7891-900.

16.
17.

Combination therapy of renal cell carcinoma or breast cancer patients with dendritic cell vaccine and IL-2: results from a phase I/II trial.

Baek S, Kim CS, Kim SB, Kim YM, Kwon SW, Kim Y, Kim H, Lee H.

J Transl Med. 2011 Oct 20;9:178. doi: 10.1186/1479-5876-9-178.

18.

Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients.

Bercovici N, Haicheur N, Massicard S, Vernel-Pauillac F, Adotevi O, Landais D, Gorin I, Robert C, Prince HM, Grob JJ, Leccia MT, Lesimple T, Wijdenes J, Bartholeyns J, Fridman WH, Salcedo M, Ferries E, Tartour E.

J Immunother. 2008 Jan;31(1):101-12.

PMID:
18157017
19.
20.

T-cell receptor gene-modified T cells with shared renal cell carcinoma specificity for adoptive T-cell therapy.

Leisegang M, Turqueti-Neves A, Engels B, Blankenstein T, Schendel DJ, Uckert W, Noessner E.

Clin Cancer Res. 2010 Apr 15;16(8):2333-43. doi: 10.1158/1078-0432.CCR-09-2897. Epub 2010 Apr 6.

Supplemental Content

Support Center